. 2006 Nov 13;51(2):732–735. doi: 10.1128/AAC.00690-06

TABLE 1.

Genotypes, phenotypes, and RCs of resistant isolates

Isolate^a	Mutation(s) in protease^b		Mutation in the following cleavage sites:		FC in IC₅₀ compared to that for WT^c							RC (% of that for WT)
Isolate^a	Amino acid at position 84	Other mutations	p7/p1	p1/p6	NFV	SQV	IDV	RTV	APV	LPV	ATV	RC (% of that for WT)
A1	I84A	L10I, M46I, L63H, A71V, V77I	A431V	WT	600	1,000	73	60	32	10	38	41
A2	I84A	L33F, M46I, L63P	NA	NA	600	141	27	85	31	NA	NA	NA
A3	I84A	L10I, M46L, L63T, A71V	NA	NA	600	365	78	76	43	11	NA	22
A4	I84A	L10F, M46I, L63P, A71V	WT	L449F	600	241	58	42	32	14	NA	2.5
A5	I84A	L10V, M46I, L63A/P, A71V	A431V	L449Q	600	256	53	54	28	9.0	NA	18
A6	I84A	L10I, M46I, L63P, A71V, L76V	A431V	WT	64	24	38	34	21	14	NA	1.0
A7	I84A	L10F, L19I, M46I, I47V, I54V, L63P, A71V	A431V	S451I	600	1,000	92	141	74	124	NA	NA
A8	I84A	L10V, K20I, M36I, M46I, A71V, G73S, L76V	A431V	WT	600	265.5	400	86	252	94	NA	6.4
A9	I84A	L10I, M46I, L63P, A71V, V77I	WT	L449F	600	1,000	138	167	33	16	52	64
A10	I84A	L10F, K20I, M46I, I54M, L63P, A71V, G73T, V77I	A431V	L449L/V, R452R/K	600	1,000	400	400	400	59	700	27
A11	I84A	L10F, M46I, L63P, A71A/V, V77V/I	A431A/V	L449F	600	1,000	73	73	47	14	63	31
A12	I84A	L10I, L33F, M46I, I54V, L63P, A71V, L76V	A431V	L449L/Q, S451T	600	1,000	400	400	400	210	25	16
A13	I84A	L10F, K20I, M36M/I, M46I, I54V, L63P, A71V, G73S	WT	R452S	196	1,000	178	400	43	50	700	5.7
A14	I84A	L10I, M46I, I47V, L63P, A71V, L76V	A431V	WT	210	69	152	105	141	104	21	0.7
A15	I84A	L10I, K20R, M36I, M46I, I54V, Q58E, L63A/T, A71V, V82V/I	A431V	WT	600	1,000	118	400	30	75	253	22
Median					600	1,000	92	86	43	33	57	18
C1	I84C		WT	WT	15	6.1	1.2	1.6	1.7	0.4	NA	12.0
C2	I84C	K20I, M36I, V82I	WT	S451N	59	14	1.3	8.6	5.4	NA	NA	11.0
C3	I84C	L10I, L19L/I, L24I, L63H	WT	L449L/F	74	56	4.1	10	8.6	1.6	NA	8.9
C4	I84C	L10F, L19L/V, L24I, M46L, L63P	A431V	L449F	395	92	11	9.1	10	3.1	NA	0.6
C5	I84C	L10L/I, K20R, M36I, M46L, L63P, V82IV/I	WT	WT	51	41	3.8	15	20	3.1	NA	15.0
C6	I84C	L10I, G16A, M46I, L63P, L76V	A431V	WT	144	24	63	22	64	47	NA	13.0
C7	I84C	L10I, L24I, M46L, L63P, A71T, G73S, V771	A431A/V	L449F	600	1,000	42	60	23	7.2	NA	1.2
C8	I84C	L10I, L19I, K20K/R, L24L/I, M46I, K55K/R, L63P	WT	WT	86	68	6.4	14	12	2.9	NA	38
C9	I84C	L10V, L24L/I, M46L, I54L, L63P	WT	WT	70	115	5.5	20	30	2.3	9.1	NA
C10	I84C	L10I, K20T, Q58E, V82I	WT	WT	286	242	5.5	29	53	5.1	19	64
C11	I84C	L10I, L24I, L63H	WT	WT	91	121	5.7	15	18	2.8	5.0	25
Median					86	68	5.5	15	18	3.0	9.1	13

Except for the patient from whom isolate A1 was obtained, the treatment histories of the patients from which the isolates were obtained are unknown.

Reference sequences were compared with baseline sequences. Polymorphisms at the following positions are not listed: 12, 13, 14, 15, 18, 33 (other than L33F), 35, 37, 39, 41, 43, 45, 57, 60, 61, 62, 64, 65, 66, 67, 69, 70, 72, 74, 83, 89, 91, 93, and 95. Samples with a mixture of sequences at a particular codon were excluded from the analysis.

The current reduced susceptibility cutoffs are 2.5 for RTV, 3.6 for NFV, 2.3 for SQV, 10 for IDV, 4.0 for APV, and 9 for LPV-RTV. For calculation purposes FC values representing 50% inhibitory concentrations (IC₅₀s) higher than the maximum measurable level were assigned an arbitrary value, based on the ratio between the highest drug concentration tested and the reference virus 50% inhibitory concentration: 600 for NFV, 1,000 for SQV, 400 for IDV and APV, 700 for ATV. NA, not available.